Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S2784-8671.24.07941-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical presentation of psoriasis on the breast of an elderly woman: A case report.
SAGE Open Med Case Rep
November 2024
Department of Dermatology, University of Texas Health Science Center at Houston, Bellaire, TX, USA.
Psoriasis is a chronic, inflammatory skin disease that affects over 60 million adults and children globally. It is classically characterized by pink plaques covered with silver scales on the extensor surfaces, trunk, or scalp. In this report, we describe the case of a woman in her late 60s with psoriasis presenting as a painful plaque on her left breast.
View Article and Find Full Text PDFLong-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study.
J Dermatolog Treat
December 2024
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Psoriasis is a chronic skin disease driven by immune system dysfunction and associated with increased cardiovascular risk and metabolic disorders. Risankizumab is an anti-interleukin-23 humanized monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. We conducted a 3-year retrospective study to evaluate the effectiveness and the safety of risankizumab in patients with moderate-to-severe psoriasis, comparing those with and without the presence of at least one cardiometabolic comorbidity (CMD).
View Article and Find Full Text PDFRisankizumab in very elderly patients in real-world practice.
Ital J Dermatol Venerol
November 2024
Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy -
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.
Arch Dermatol Res
October 2024
1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, I. Dragoumi 5, Athens, 161 21, Greece.
Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study.
Arch Dermatol Res
September 2024
Faculty of Medicine, Department of Dermatology and Venereology, Uşak University, Uşak Training and Research Hospital, Uşak, Turkey.
Psoriasis is a chronic inflammatory skin condition associated with systemic inflammation and a higher risk of cardiovascular comorbidities. This study retrospectively evaluates coagulation parameters in psoriasis vulgaris patients treated with IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (risankizumab, guselkumab), compared to those untreated systemically. The study reviewed records from 177 patients treated between January 2019 and March 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!